An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma

Molecular Medicine

Volumn 5, Issue 3, 1999, Pages 181-191

  Chesney, Jason ^a   Metz, Christine ^a   Bacher, Michael ^a   Peng, Tina ^a   Meinhardt, Andreas ^b   Bucala, Richard ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLUCOCORTICOID; GROWTH FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HISTOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0033015445     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402061     Document Type: Article

References (41)

1. Nicholson GL. (1987) Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res. 47: 1473-1487.
2. Folkman J. (1986) How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res. 46: 467-473.
3. Muul LM, Spiess PJ, EP Director, Rosenberg SA. (1987) Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138: 989-995.
4. Pugh-Humphreys RGP, Woo J, Thomson AW. (1991) Cytokines and their receptors as potential therapeutic targets. In: The Cytokine Handbook. Academic Press, New York, pp. 357-386.
5. Lang RA, Burgess AW. (1990) Autocrine growth factors and tumourigenic transformation. Immunol. Today 11: 244-249.
6. Barnard JA, Lyons RM, Moses HL. (1990) The cell biology of transforming growth factor beta. Biochim. Biophys. Acta 1032: 79-87.
7. Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB. (1988) TGF-beta: possible roles in carcinogenesis. Br. J. Cancer 57: 594-600.
8. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MK, Strieter RM. (1996) Inhibition of IL-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 97: 2792-2802.
9. David JR. (1996) Delayed hypersensitivity in vitro: its mediation by cell free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. U.S.A. 56: 72-77.
10. Bloom BR, Bennet B. (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153: 80-82.
11. Bacher MB, Metz CN, Calandra T, et al. (1996) An essential role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. U.S.A. 93: 7849-7854.
12. Calandra T, Bernhagen J, Mitchell RA, Bucala R. (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179: 895-1902.
13. Calandra T, Bernhagen J, Metz CN, et al. (1995) MIF as a glucocorticoid-induced counter-regulator of cytokine production. Nature 377: 68-71.
14. Bernhagen J, Calandra T, Mitchell RA, et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759.
15. Bernhagen J, Bacher M, Calandra T, et al. (1996) An essential role for MIF in the tuberculin delayed-type hypersensitivity reaction. J. Exp. Med. 183: 277-282.
16. Calandra T, Spiegel LA, Metz CN, Bucala R (1998) Macrophage migration inhibitory factor (MIF) is a critical mediator of the activation of immune cells by exotoxins of gram-positive bacteria. Proc. Natl. Acad. Sci. U.S.A. 95: 11383-11388.
17. Kemp JD, Cardillo T, Stewart BC, et al. (1995) Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate IgG monoclonal antibodies against the transferrin receptor. Cancer Res. 55: 3817-3824.
18. Taetle R, Rosen F, Abramson I, Venditti J, Howell S. (1987) Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treatment Rep. 71: 297-304.
19. Zar JH. (1984) Biostatistical Analysis. Prentice-Hall, Englewood Cliffs, NJ.
20. Waeber G, Calandra T, Roduit R, et al. (1997) Insulin secretion is regulated by the glucose-dependent production of islet β-cell macrophage migration inhibitory factor (MIF). Proc. Natl. Acad. Sci. U.S.A. 94: 4782-4787.
21. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. (1994) Purification, bioactivity, and secondary structure analysis of mouse and human MIF. Biochemistry 33: 14144-14155.
22. Passanti A, Taylor RM, Pili R, et al. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor Lab. Invest. 67: 519-528.
23. Bergman Y, Haimovich J. (1977) Characterization of a carcinogen-induced murine B lymphocyte cell of C3H/eB origin. Eur. J. Immunol. 7: 413-417.
24. Campbell MJ, Esserman L, Levy R. (1988) Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J. Immunol. 141: 3227-3233.
25. Basham TY, Palladin MA, Badger CC, Bernstein ID, Levy R, Merigan TC. (1988) Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B cell and T cell lymphomas. Cancer Res. 48: 4196-4200.
26. Kaminski MS, Kitamura K, Maloney DG, Levy R. (1987) Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol. 138: 1289-1296.
27. Folkman J, Cotran R. (1976) Relation of vascular proliferation to tumor growth. Int. Rev. Exp. Pathol. 16: 207-248.
28. Gimbrone MA, Leapman SB, Cotran R, Folkman J. (1972) Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136: 261-276.
29. Folkman JK, Watson D, Ingber D, Hanahan J. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
30. Vecchi AC, Garlanda C, Lampugnani MG, et al. (1994) Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur. J. Cell Biol. 63: 247-254.
31. Xie Y, Muller WA. (1993) Molecular cloning and adhesive properties of murine platelet/endothelial adhesion molecule-1. Proc. Natl. Acad. Sci. U.S.A. 90: 5569-5573.
32. DeLisser HM, Newman PJ, Albeda SM. (1993) Platelet endothelial cell adhesion molecule (CD31). Curr. Top. Microbiol. Immunol. 184: 37-45.
33. Buck CA, Baldwin HS, DeLisser H, et al. (1993) Cell adhesion receptors and early mammalian heart development - an overview. C R Acad. Sci. III 316: 849-859.
34. Bacher MB, Meinhardt A, Lan HY, et al. (1997) Migration inhibitory factor expression in experimentally induced endotoxemia. Am. J. Pathol. 150: 235-246.
35. Whalen GF, Zetter BR. (1992) Angiogenesis. In: Wound Healing, W. B. Saunders, Philadelphia, pp. 77-95.
36. Folkman J, D'Amore PA. (1996) Blood vessel formation: what is its molecular basis? Cell 87: 1153-1155.
37. Fiorentino MV. (1991) Lymphomas in the elderly. Leukemia 5: 79-85.
38. Goss PE. (1992) New perspectives in the treatment of non-Hodgkin's lymphoma. Semin. Oncol. 19: 23-29.
39. Zackheim HS. (1994) Treatment of cutaneous T-cell lymphoma. Semin. Dermatol. 13: 207-215.
40. Sun HW, Bernhagen J, Bucala R, Lolis E. (1996) Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. U.S.A. 93: 5191-5196.
41. Rosengren E, Bucala R, Aman P, et al. (1996) The immunoregulatory mediator MIF catalyzes a tautomerization reaction. Mol. Med. 2: 143-149.